Immunome Company Leadership

Immunome Management Team Effectiveness

The company has return on total asset (ROA) of (0.4648) % which means that it has lost $0.4648 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9304) %, meaning that it created substantial loss on money invested by shareholders. Immunome's management efficiency ratios could be used to measure how well Immunome manages its routine affairs as well as how well it operates its assets and liabilities. As of the 31st of January 2026, Return On Tangible Assets is likely to drop to -1.15. In addition to that, Return On Capital Employed is likely to drop to -1.55. At this time, Immunome's Total Assets are very stable compared to the past year. As of the 31st of January 2026, Non Current Assets Total is likely to grow to about 22.8 M, while Other Assets are likely to drop 0.86. As of the 31st of January 2026, Common Stock Shares Outstanding is likely to grow to about 70.8 M, though Net Loss is likely to grow to (32.1 M). Immunome has a total of 110.34 Million outstanding shares. The majority of Immunome outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Immunome to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Immunome. Please pay attention to any change in the institutional holdings of Immunome as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Immunome in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Immunome, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Immunome Workforce Comparison

Immunome Insider Trading History

Immunome Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Immunome often depends on how effective the management is. Immunome management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Immunome management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Immunome management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Will Biotechnology sector continue expanding? Could Immunome diversify its offerings? Factors like these will boost the valuation of Immunome. Market participants price Immunome higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Immunome data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Understanding Immunome requires distinguishing between market price and book value, where the latter reflects Immunome's accounting equity. The concept of intrinsic value—what Immunome's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Immunome's price substantially above or below its fundamental value.

Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Immunome's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.